企業プロフィール

Adaptive Biotechnologies 株価・ニュース・カタリスト

ティッカー:
ADPT
取引所:
NASDAQ
セクター:
MedTech
所在地:
United States

株価パフォーマンス

24.77 USD (+0.12%)

終値

最終更新: 2026年8月17日

2.42B USD

時価総額

株価変動の要因

As of Aug 17, 2026, ADPT was little changed and closed at $24.77. No new same-company headline was identified in the current news window.

企業概要

Adaptive Immune-System Platform

Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics.

Minimal Residual Disease

The company’s commercial MRD business is led by clonoSEQ, a sequencing-based test used to detect and monitor residual disease in blood cancers. Clinical testing and biopharmaceutical drug-development applications make MRD the company’s principal commercial engine.

Immune Medicine

Adaptive also applies its platform to characterize immune responses and identify disease-specific immune signatures. This business supports biopharmaceutical partnerships and longer-term diagnostic and therapeutic opportunities in cancer and autoimmune disease.

今後のカタリスト

  • Adaptive still has a clean platform story in immune-system diagnostics and therapeutics, but the commercial side is where the company has to keep proving itself. The update is less about one binary event and more about whether the core immune products continue to move from scientific capability into routine clinical use.

最近のニュース

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

類似銘柄

事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。